A Study of STSA-1002 in Healthy Subjects

NCT05497635 | Completed Phase 1

• 1 other identifier: STSA-1002-03
• Study Type: interventional
• Target: 26
• Locations: 1 country
• Sites: 2

Brief Summary

This study is a Phase Ib, randomized, double-blind, placebo-controlled, multiple dose, dose escalation safety, tolerability,pharmacokinetic and pharmacodynamic study of STSA-1002 injection in healthy subjects. A total of 26 healthy subjects were enrolled in three dosage groups.

Conditions

Healthy Subject

Outcome Measures

Primary Outcomes (15)

• Incidence of Adverse Events、Clinically Significant Laboratory Abnormalities、Clinically Significant Electrocardiogram、Vital Signs And Physical Examination Abnormalities.

  To evaluate the safety and tolerability of multiple intravenous administration of STSA-1002 in healthy adult subjects.

  Up to Study Day 56

• Maximum plasma concentration (Cmax)

  To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

  From Day 0 to Day 56

• Area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t)

  To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

  From Day 0 to Day 56

• Area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)

  To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

  From Day 0 to Day 56

• Time of maximum concentration (Tmax)

  To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

  From Day 0 to Day 56

• Elimination half-life (t1/2)

  To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

  From Day 0 to Day 56

• Mean residence time (MRT)

  To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

  From Day 0 to Day 56

• Clearance (CL)

  To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

  From Day 0 to Day 56

• Apparent volume of distribution (Vz)

  To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

  From Day 0 to Day 56

• Maximum Concentration of the Analyte in Plasma at steady state(Cmax, ss)

  To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects

  From Day 0 to Day 56

• Minimum Measured Concentration of the Analyte in Plasma at Steady State(Cmin, ss)

  To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects

  From Day 0 to Day 56

• Time-averaged concentration at steady state(Cav, ss)

  To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects

  From Day 0 to Day 56

• Area under the concentration curve from time 0 extrapolate to infinite time(AUCinf,ss)

  To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects

  From Day 0 to Day 56

• Degree of fluctuation(DF)

  To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects

  From Day 0 to Day 56

• Accumulation factor

  To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects

  From Day 0 to Day 56

Secondary Outcomes (2)

• Change from baseline in concentration of free C5a and anti-drug antibody

  From Day 0 to Day 56

• Change from baseline in concentration of Myeloperoxidase（MPO）、Neutrophil elastase（NE）、Proteinase3（PR3）、 C-X-C chemokine receptor 1(CXCR1)

  From Day 0 to Day 56

Study Arms (3)

A low dose of group

EXPERIMENTAL

All subjects will be randomized to receive low dose of STSA-1002 or dose-matched placebo.

Drug: STSA-1002 Injection; Drug: Placebo

A middle dose of group

EXPERIMENTAL

All subjects will be randomized to receive middle dose of STSA-1002 or dose-matched placebo.

Drug: STSA-1002 Injection; Drug: Placebo

A high dose of group

EXPERIMENTAL

All subjects will be randomized to receive high dose of STSA-1002 or dose-matched placebo.

Drug: STSA-1002 Injection; Drug: Placebo

Interventions

STSA-1002 Injection DRUG

Intravenous injection

A high dose of group; A low dose of group; A middle dose of group

Placebo DRUG

Intravenous injection

A high dose of group; A low dose of group; A middle dose of group

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy subjects, aged ≥ 18 but ≤ 45, male and female.
• Weight:Male≥50.0kg,Female≥45kg;Body mass index: 19.0-26.0 kg/m2, inclusive.
• Medical history, vital signs, physical examination, laboratory examination (including blood routine, urine routine, blood biochemistry, coagulation function test, etc.) and all tests related to the test were normal or abnormal as determined by the researcher and had no clinical significance.
• Subjects (including their partners) must take effective contraceptive measures and have no birth plan or sperm or egg donation plan during the trial period and within 6 months after the end of the last administration.
• Subjects are aware of the content, process and possible adverse reactions of the study and voluntarily signed the informed consent form(ICF).

You may not qualify if:

• History of tuberculosis; or combined with mixed lymphocyte culture + interferon assay results, chest imaging comprehensive evaluation of tuberculosis infection (if necessary, tuberculosis experts should be jointly evaluated).
• Any clinically serious diseases such as respiratory, circulatory, digestive, urinary, blood, endocrine, neurological or mental disorder, or a history of the above diseases or any other diseases or physiological conditions that can interfere with the test results.
• With any major surgical or surgical that possibly affects drug absorption, distribution, metabolism or excretion(Except appendicitis) within 2 months before screening or plan to undergo surgery during the study period.
• Subjects with allergies or allergies to any components of the investigational drug and its excipients(such as allergies to two or more drugs, food, pollen), or the IgE is higher than the upper limit of normal.
• Positive screening test results for human immunodeficiency virus (HIV) antibodies, syphilis-specific antibody, hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCVAb).
• Subjects with abnormal blood white blood cell count and absolute neutrophil count during the screening period with clinical significance; or hemoglobin: male \<120g/L or female \<110g/L.
• Drug abuse within 1 year before screening \[such as morphine, ketamine (K powder), THC (marijuana), methamphetamine (ice), MDMA (ecstasy) ), cocaine, etc.\]; or positive urine screening for drug abuse.
• Subjects who have taken drugs that may affect immune function within 6 months before screening, have received any monoclonal antibody or biological agent for treatment (for any illness) within the previous 3 months, and have taken prescription drugs,non-prescription drugs,chinese herbal medicine within 14 days before screening.
• Alcoholism within 6 months before screening (drinking more than 14 units of alcohol per week: 1 unit = 285mL of beer, or 25mL of spirits, or 100mL of wine) or unable to stop consuming any alcoholic products after enrollment until the entire study period or a positive alcohol breath test result.
• Subjects who smoking (more than 5 cigarettes per day on average) within 3 months before screening or who could not stop using any tobacco products until the whole study period after enrollment.
• Subjects who drink too much (more than 8 cups a day, 1 cup = 200 mL) of tea, coffee and other beverages rich in xanthine within 3 months before screening, or food or beverages that affect drug absorption, distribution, metabolism, and excretion.
• Donation of blood or lost more than 400ml within 3 months before the first investigational product administration or plan to donate blood or blood components during the study period or within 3 months after the end of the study, or have a history of blood transfusion within 4 weeks before the first drug use of the study.
• Subjects who participated in any unmarked drug, vaccine or medical device clinical trial within 3 months before screening and applied the drug, vaccine or medical device in the trial.
• Vaccination within 14 days before the first dose or ready to be vaccinated during the study period to 2 months after the end of the study.
• Subjects who have used long-acting estrogen or progestogen injections or implants within 6 months before the study or those who have used short-acting contraceptives within 4 weeks before the study.

Sponsors & Collaborators

• Staidson (Beijing) Biopharmaceuticals Co., Ltd: lead

Study Sites (2)

Beijing Shijitan Hospital, Capital Medical University

Beijing, Beijing Municipality, 102600, China

Location

The Second Affiliated Hospital Of Xingtai Medical College

Xingtai, Hebei, 054000, China

Location

Study Officials

• Xinghe Wang, Ph.D

  Beijing Shijitan Hospital, Capital Medical University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 1, 2022
• First Posted: August 11, 2022
• Study Start: October 14, 2022
• Primary Completion: April 6, 2023
• Study Completion: April 6, 2023
• Last Updated: April 18, 2023

Record last verified: 2023-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (2)